zurück

Dupilumab (new indication: asthma bronchiale, patients aged ≥ 6 bis ≤ 11)


Subject:

  • Active Substance: Dupilumab
  • Name: Dupixent®
  • Therapeutic area: Asthma
  • Pharmaceutical company: Sanofi-Aventis Deutschland GmbH

 

Time table:

  • Start: 15.04.2022
  • Final decision by G-BA: 06.10.2022


Final decision:

  • No additional benefit proved